Biogen
BIIB
Performance
About Biogen
Biogen is a global biotechnology company focused on discovering, developing, and delivering innovative medicines for serious neurological and rare diseases such as multiple sclerosis, Alzheimer's disease, ALS, spinal muscular atrophy, and lupus. Leveraging deep expertise in human biology and multiple therapeutic modalities, Biogen advances first‑in‑class treatments through extensive R&D, clinical trials, and early‑access programs, while emphasizing health equity, sustainability, and patient advocacy across its worldwide operations.
Recent News
WHCD Shooting, DOJ Ends Powell Probe, Musk Vs. Altman and More in Morning Squawk
Eisai, Biogen Receive Extended FDA Review for Lecanemab Subcutaneous Starting Dose
Biogen Seals $5.3 B Deal for Apellis, Adds Two Blockbuster Drugs
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Clinical Trial Failures of 2026
STAT+: Biogen’s Tau-Targeting Alzheimer’s Drug Posts Mixed Results in Mid-Stage Study
Is Biogen Inc. (BIIB) One of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
FDA Pushes Leqembi Subcutaneous Start‑Dose Review to Aug. 24, 2026
Biogen, Denali to Drop Drug in Non-Genetic Parkinson’s After Mid-Stage Study Flop
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
US Stock Market Today: Dow, S&P 500 Futures Flat Ahead of Fed Decision, Megacap Earnings
FDA Delays Leqembi Decision; Artiva Raises $300M; Pharvaris Prices Offering
Whoop Secures $575 M Series G, Hits $10 B Valuation Ahead of IPO
Nanoparticle Therapy Erases Alzheimer Plaques in Mice, Restores Cognition
PharmaShots Magazine-April-2026 Edition
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
STAT+: Closely Watched Experimental Parkinson’s Drug Fails Key Clinical Trial
Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.
With Growth Curve Trending up, Biogen Looks to Early-Stage Assets for ‘Next Generation’
FDA, up Close and Personal: A Banker’s Recalibration
What’s the Deal with Alzheimer’s Disease and Amyloid?
Here Are Tuesday's Biggest Analyst Calls: Apple, Tesla, Amazon, GM, Crocs, Viking, Alphabet, Ford & More
Q&A: Nephrologist on ‘Evolving’ Field of Kidney Transplantation
Biogen Ready to Catch Alzheimer’s Patients Transitioning Off Lilly’s Kisunla
ShinyHunters Group Targets Over 100 Enterprises, Including Canva, Atlassian, and Epic Games
Dayra Therapeutics Secures Over $70M in Committed Funding
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Goldman Sachs Sets New Biogen Stock Price Target on Bold Alzheimer's Bet
Eli Lilly Shares Surge on a Beat-and-Raise, Proving the Stock's Swoon Was a Mistake
Ocrelizumab Preserves Ambulation, Hand Function in MS
Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain
Top Biotech Deals in March 2026
Biogen, with $5.6B Apellis Buy, Builds Out Immunology Offerings
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
Biogen-Ionis Tau Antisense Drug Shows Cognitive Slow‑down in Early Alzheimer’s Phase 2
Diagnostics Lag Is Holding Back New Therapies, Says Study
Leqembi Starts to Deliver for Eisai and Biogen
New Antidepressants: Tackling Treatment Resistant Depression
Are We Ready for the Next Wave of Proximity Degraders?
Medicare Spending on New Alzheimer’s Drugs Falls Short of Billion‑Dollar Forecasts
Biogen Seeks Darzalex Rivalry in China for Multiple Myeloma with Felzartamab Deal
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Could Alzheimer's Be Predicted with a Finger-Prick Test?
The FDA Has Released Draft Guidance for NAMs Validation – Now What?
Biogen’s Alzheimer’s Results Bolster Tau Theory—And Denali’s Next Gen Candidate
The New Gold Rush in Brain Science
MarketBeat Week in Review – 05/18 - 05/22
Roche Gets Second European Approval for Alzheimer’s Test
Biogen, Eisai Hit with 3-Month Delay for Starting SubQ Alzheimer’s Therapy